COMPUGEN LTD (CGEN)

IL0010852080 - Common Stock

1.92  +0.02 (+1.05%)

Fundamental Rating

3

Taking everything into account, CGEN scores 3 out of 10 in our fundamental rating. CGEN was compared to 59 industry peers in the Life Sciences Tools & Services industry. CGEN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, CGEN is valued expensive at the moment.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CGEN has reported negative net income.
In the past year CGEN has reported a negative cash flow from operations.
CGEN had negative earnings in each of the past 5 years.
CGEN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -15.46%, CGEN is doing worse than 62.71% of the companies in the same industry.
CGEN's Return On Equity of -28.61% is on the low side compared to the rest of the industry. CGEN is outperformed by 64.41% of its industry peers.
Industry RankSector Rank
ROA -15.46%
ROE -28.61%
ROIC N/A
ROA(3y)-25.7%
ROA(5y)-29.88%
ROE(3y)-34.67%
ROE(5y)-40.04%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 94.01%, CGEN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Gross Margin of CGEN has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.04%
GM growth 5Y-0.04%

More info and screens

6

2. Health

2.1 Basic Checks

CGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGEN has been increased compared to 1 year ago.
The number of shares outstanding for CGEN has been increased compared to 5 years ago.
There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CGEN has an Altman-Z score of -2.85. This is a bad value and indicates that CGEN is not financially healthy and even has some risk of bankruptcy.
CGEN has a Altman-Z score of -2.85. This is amonst the worse of the industry: CGEN underperforms 84.75% of its industry peers.
CGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.85
ROIC/WACCN/A
WACC10.61%

2.3 Liquidity

CGEN has a Current Ratio of 4.36. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
CGEN has a better Current ratio (4.36) than 64.41% of its industry peers.
A Quick Ratio of 4.36 indicates that CGEN has no problem at all paying its short term obligations.
The Quick ratio of CGEN (4.36) is better than 74.58% of its industry peers.
Industry RankSector Rank
Current Ratio 4.36
Quick Ratio 4.36

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.00% over the past year.
CGEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 346.12%.
Measured over the past years, CGEN shows a quite strong growth in Revenue. The Revenue has been growing by 13.45% on average per year.
EPS 1Y (TTM)45%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q375%
Revenue 1Y (TTM)346.12%
Revenue growth 3Y155.76%
Revenue growth 5Y13.45%
Revenue growth Q2Q346.12%

3.2 Future

CGEN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.40% yearly.
The Revenue is expected to grow by 27.23% on average over the next years. This is a very strong growth
EPS Next Y100.31%
EPS Next 2Y-16.62%
EPS Next 3Y-29.34%
EPS Next 5Y-0.4%
Revenue Next Year71.56%
Revenue Next 2Y2.25%
Revenue Next 3Y-5.42%
Revenue Next 5Y27.23%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 2809.48, the valuation of CGEN can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CGEN is on the same level as its industry peers.
The average S&P500 Price/Forward Earnings ratio is at 21.63. CGEN is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 2809.48

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A cheap valuation may be justified as CGEN's earnings are expected to decrease with -29.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.62%
EPS Next 3Y-29.34%

More info and screens

0

5. Dividend

5.1 Amount

CGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPUGEN LTD

NASDAQ:CGEN (4/26/2024, 3:30:00 PM)

1.92

+0.02 (+1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap171.90M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 2809.48
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.46%
ROE -28.61%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 94.01%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.36
Quick Ratio 4.36
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)45%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y100.31%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)346.12%
Revenue growth 3Y155.76%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y